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Objectives. This study sought to compare stenting of the
primary infarct-related artery (IRA) with optimal primary percu-
taneous transluminal coronary angioplasty (PTCA) with respect
to clinical and angiographic outcomes of patients with an acute
myocardial infarction.
Background. Early and late restenosis or reocclusion of the IRA
after successful primary PTCA significantly contributes to in-
creased patient morbidity and mortality. Coronary stenting re-
sults in a lower rate of angiographic and clinical restenosis than
standard PTCA in patients with angina and with previously
untreated, noncomplex lesions.
Methods. After successful primary PTCA, 150 patients were
randomly assigned to elective stenting or no further intervention.
The primary end point of the trial was a composite end point,
defined as death, reinfarction or repeat target vessel revascular-
ization as a consequence of recurrent ischemia within 6 months of
randomization. The secondary end point was angiographic evi-
dence of restenosis or reocclusion at 6 months after randomiza-
tion.
Results. Stenting of the IRA was successful in all patients
randomized to stent treatment. At 6 months, the incidence of the
primary end point was 9% in the stent group and 28% in the PTCA
group (p 5 0.003); the incidence of restenosis or reocclusion was
17% in the stent group and 43% in the PTCA group (p 5 0.001).
Conclusions. Primary stenting of the IRA, compared with
optimal primary angioplasty, results in a lower rate of major
adverse events related to recurrent ischemia and a lower rate of
angiographically detected restenosis or reocclusion of the IRA.
(J Am Coll Cardiol 1998;31:1234–9)
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Early and late recurrent ischemia, as a consequence of resten-
osis or reocclusion of the infarct-related artery (IRA) after
successful primary percutaneous transluminal coronary angio-
plasty (PTCA), is a major pitfall of primary PTCA therapy for
acute myocardial infarction (AMI). Within 6 months of infarc-
tion, restenosis or reocclusion may occur in .50% of patients
(1–3), and the incidence of major adverse events related to
recurrent ischemia, such as death, reinfarction or repeat target
vessel revascularization, may be as high as 30% (2,4,5).
Unplanned stenting of the IRA for a suboptimal or poor
angiographic result after primary PTCA, may be safely per-
formed and results in good clinical outcome (i.e., low rates of
in-hospital recurrent ischemia and related major adverse
events) (6–9). Primary stenting in AMI would be expected to
improve both early and late outcomes if the rate of IRA artery
restenosis and reocclusion were reduced compared with that
for PTCA.
The extent to which primary stenting of the IRA may
improve the long-term patient outcome has not been deter-
mined. The Florence Randomized Elective Stenting in Acute
Coronary Occlusions (FRESCO) trial is a randomized trial
comparing primary stenting of the IRA with optimal PTCA
with respect to the clinical and angiographic outcomes of
patients with an AMI.
Methods
Patient selection. Criteria for enrollment included 1) chest
pain persisting .30 minutes associated with ST segment
elevation of at least 0.1 mV in two or more contiguous
electrocardiographic (ECG) leads; and 2) admission within 6 h
of symptom onset, as well as admission between 6 and 24 h if
there was evidence of continuing ischemia. Patients with
cardiogenic shock were included. Cardiogenic shock was con-
firmed at cardiac catheterization by a systolic blood pressure
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,90 mm Hg and a left ventricular filling pressure $20 mm Hg.
No upper age limit was used. The exclusion criteria included
previous administration of fibrinolytic treatment and inability
to provide informed consent.
Study protocol. Angiographic criteria for exclusion from
PTCA included 1) stenosis of the IRA of ,70%, and 2)
inability to identify the IRA. Primary PTCA had to be at-
tempted in all patients who met inclusion criteria. Primary
PTCA was accomplished with the use of standard techniques;
an attempt was made to reduce the degree of residual stenosis
in all lesions within the IRA to ,30% with the use of high
pressure inflations and moderately oversized balloons as
needed. After an optimal acute angiographic result was
achieved (i.e., a residual stenosis ,30% with restoration of
Thrombolysis in Myocardial Infarction [TIMI] grade 3 flow
[10]) and informed consent was obtained, patients were ran-
domly assigned to either primary stenting or no further inter-
vention. Randomization was performed by means of sealed
envelopes. The only criterion for exclusion from randomiza-
tion was a reference vessel diameter ,2.5 mm. Patients
considered for the study but in whom PTCA was nonoptimal
were not randomized. These patients were studied in a sepa-
rate parallel registry. Stenting of the target lesion was accom-
plished using the Gianturco-Roubin coronary stent (Cook,
Inc.) as the first-choice device; other types of stents could be
used after Gianturco-Roubin stent deployment failure or to
complete stenting treatment after successful Gianturco-
Roubin stent deployment. In patients randomized to stenting,
attempted stenting was mandatory irrespective of the coronary
anatomy. Evidence of coronary thrombus or the presence of
diffuse disease or severe vessel tortuosity was not considered a
contraindication to stenting. Coronary stenting was performed
using standard techniques, including high pressure (.13 atm)
dilations after stent deployment.
In both groups, intravenous heparin was administered for 3
days. Patients were routinely treated with aspirin (325 mg/day
indefinitely) and ticlopidine (500 mg/day for 2 months).
For patients who could not be randomized because of a
nonoptimal angiographic result after primary PTCA, stenting
of the IRA was recommended if there was persistent occlusion
or residual stenosis .50% or angiographic evidence of occlu-
sive dissection after one or more dilations with appropriately
sized balloons.
Coronary angiography was required for all patients at 48 to
72 h, at 1 month and at 6 months after the procedure.
Unscheduled angiography was allowed on the basis of clinical
indication. Nonrandomized patients had clinical and angio-
graphic follow-up as well.
The study protocol was approved by the local ethics com-
mittee.
Angiographic analysis. Quantitative coronary angiography
was performed with the use of an automatic edge detection
system (Siemens Ancor). Coronary occlusion was assigned a
value of 0 mm for minimal lumen diameter (MLD) and 100%
for percent diameter stenosis. Coronary flow in the IRA was
graded according to TIMI flow grade (10). Collateral flow was
graded according to the classification developed by Rentrop et
al. (11). Multivessel disease was defined as at least one major
non–infarct-related coronary artery with .50% stenosis. An
optimal acute angiographic result was defined as residual steno-
sis ,30% associated with TIMI grade 3 flow. A suboptimal
angiographic result was defined as residual stenosis .30%
associated with TIMI grade 3 flow or residual stenosis ,30%
associated with TIMI grade 2 flow. Unsuccessful PTCA was
defined as PTCA resulting in TIMI grade 0 or 1 flow, whatever
the residual stenosis. Left ventricular ejection fraction was
calculated by digitization of the ventricular outline in diastolic
and systolic frames from ventriculograms performed in the
right anterior oblique projection. Analysis immediately after
PTCA, at 48 to 72 h, at 1 month and at 6 months was
performed using identical projections.
End points. The primary end point of the trial was a
composite clinical end point defined as the occurrence of one
of the following events: death, reinfarction, or repeat target
vessel revascularization as a consequence of recurrent isch-
emia within the first 6 months after initial revascularization.
Patients with more than one event were assigned the highest
ranked event according to the previous list. Recurrent ischemia
was defined as ischemic chest pain with either new ST segment
or T wave changes at rest or on exercise testing. Reinfarction
was defined as recurrent chest pain with new ST segment
elevation and recurrent elevation of cardiac enzymes. Repeat
revascularization of the target vessel was defined as PTCA or
bypass surgery performed because of restenosis or reocclusion
of the target lesion in association with objective evidence of
recurrent ischemia. Hemorrhagic and vascular complications
were defined as hemorragic stroke, bleeding requiring trans-
fusion or vascular surgery.
The secondary end point was angiographic evidence of
restenosis or reocclusion, defined as at least 50% stenosis of
the target lesion on the scheduled or unscheduled follow-up
angiogram.
Statistical analysis. The sample size was calculated on the
assumption that the primary end point would occur in 30% of
patients who underwent conventional PTCA and in 10% of
those who underwent primary coronary stenting. Thus, 59
patients were required in each group to test for an absolute
reduction of 20% with p value of .05 and a power of 80%.
Accounting for adverse events other than those included in the
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
ECG 5 electrocardiographic
FRESCO 5 Florence Randomized Elective Stenting in
Acute Coronary Occlusions (trial)
IRA 5 infarct-related artery
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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primary end point and withdrawal, it was expected that at least
75 patients/group would be available for analysis. Analyses
were performed on an intention to treat basis. Continuous data
are summarized as mean value 6SD. Chi-square test analysis
was used for comparison of categoric variables. Analysis of
variance was used to test differences among continuous vari-
ables. Kaplan-Meier survival curves were used to characterize
the timing of the primary study end point during the follow-up
period. Comparison of survival curves was performed using the
log-rank test. Multivariate analysis using a logistic regression
model was performed to identify correlates of recurrent isch-
emia. Factors analyzed included age, gender, previous myocar-
dial infarction, anterior location of the current infarction,
presence of collateral vessels, time to reperfusion, primary
stenting of the IRA, postprocedural MLD. Odds ratios and
their 95% confidence intervals were calculated. A p value
,0.05 was considered significant. Statistical tests were per-
formed using GB-STAT system (Dynamic Microsystem).
Results
Patients. Between January 1996 and March 1997, 223
patients eligible for primary PTCA were enrolled. Primary
PTCA was successful in 220 patients (99%). After successful
primary angioplasty, 70 patients (32%) were not randomized
because of an initial suboptimal acute angiographic result (66
patients) or a reference vessel diameter ,2.5 mm (4 patients),
whereas 150 patients with an optimal angiographic result were
randomized either to elective stenting or no further interven-
tion. The baseline clinical and angiographic characteristics of
all 223 patients are shown in Table 1. There were significant
differences between nonrandomized and randomized patients.
The former had a greater incidence of anterior AMI, cardio-
genic shock, severe left ventricular dysfunction and multivessel
disease. Between randomized groups, more patients with an
anterior AMI were assigned to the stent group than to the
PTCA group, but the two groups were well matched with
respect to other clinical and angiographic characteristics.
Procedural data and angiographic analysis. Procedural
data are shown in Table 2. Stents were successfully placed in all
75 patients randomly assigned to this therapy, and 17 patients
(23%) had multiple-stent implantation. All patients received at
least one Gianturco-Roubin stent 20 mm in length. Other types
of stents, ,20 mm long, were used in 12 patients to complete
stenting treatment of the target lesion or other focal lesions
within the IRA. Seventy-four patients had a final optimal
angiographic result after stent placement. One patient had
temporary deterioration of flow (TIMI grade 2 flow) after high
pressure balloon stent expansion, without any evidence of
residual stenosis or dissection; at the first control angiogram at
72 h, TIMI grade 3 flow was revealed. After the procedure, a
larger mean MLD was achieved in the stent group than in the
PTCA group (3.33 6 0.43 vs. 3.03 6 0.46 mm, p , 0.01).
Coronary stenting was attempted in 58 (88%) of 66 non-
randomized patients with a nonoptimal acute angiographic
result. There were no stent deployment failures, and 24
patients (41%) had multiple-stent implantation to treat diffuse
disease of the IRA. Stenting was not attempted in eight
patients with diffuse disease of the IRA and a residual stenosis
,50% associated with TIMI grade 3 flow. Overall, a final
optimal acute angiographic result was achieved in nonrandom-
ized 62 (85%) patients, and the resulting MLD was similar to
that of the stent group and larger than that of the PTCA group
(3.31 6 0.57 vs. 3.03 6 0.46 mm, p , 0.01).
No patient received fibrinolytic agents or glycoprotein
IIb/IIIa inhibitors.
Clinical and angiographic outcomes of randomized patient
groups. Clinical follow-up data were available for all patients
and are shown in Table 3. The 1-month recurrent ischemia rate
was 3% in the stent group, and 15% in the PTCA group (p 5
0.009). In the stent group, recurrent ischemia resulted in
nonfatal reinfarction in one patient and emergency repeat
PTCA in another. In the angioplasty group, recurrent ischemia
resulted in nonfatal reinfarction in two patients, and nine, all
with angiographic evidence of occlusive or subocclusive dissec-
tion, had repeat PTCA and rescue stenting. In the PTCA
group, three patients (4%), all with cardiogenic shock on
admission, died of refractory cardiogenic shock, without any
clinical or ECG evidence of IRA reocclusion. The incidence of
bleeding and vascular complications was identical in the two
groups (4%).
Table 1. Baseline Clinical and Angiographic Patient Characteristics
Nonrandomized
Group
(n 5 73)
PTCA
Group
(n 5 75)
Stent
Group
(n 5 75)
Age (yr) 64 6 11 61 6 12 62 6 12
Range 39–89 28–86 34–87
.75 yr 10 (14%) 10 (13%) 12 (16%)
Men 58 (79%) 60 (80%) 56 (75%)
Diabetes 11 (15%) 6 (8%) 13 (17%)
Killip class $II 34 (47%)* 23 (31%) 25 (33%)
Prior CABG 0 0 0
Prior PTCA 1 (1%) 3 (4%) 1 (1%)
Prior MI 9 (12%) 6 (8%) 6 (8%)
Current ant MI 43 (59%) 29 (39%)* 41 (55%)
Cardiogenic shock 18 (25%)* 7 (9%) 7 (9%)
Multivessel disease 46 (63%)* 33 (44%) 34 (45%)
LVEF† 44 6 14‡ 52 6 12 50 6 14
IRA
LAD 44 (60%)* 29 (39%) 40 (54%)
LCx 6 (8%) 6 (8%) 4 (5%)
RCA 23 (32%)* 40 (53%) 31 (41%)
Ref vessel diam (mm) 3.19 6 0.48 3.19 6 0.47 3.19 6 0.43
Time to admission (min) 162 6 95 137 6 74 152 6 95
Time to treatment (min) 30 6 24 28 6 18 28 6 21
*p , 0.05 by chi-square test for comparison among the three groups.
†Baseline left ventricular angiography was available for 189 patients. ‡p , 0.05
by analysis of variance for comparison among the three groups. Data presented
are mean value 6 SD, range or number (%) of patients. ant 5 anterior;
CABG 5 coronary artery bypass graft surgery; diam 5 diameter; IRA 5
infarct-related artery; LAD 5 left anterior descending coronary artery; LCx 5
left circumflex coronary artery; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty;
RCA 5 right coronary artery; Ref 5 reference.
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Late recurrent ischemia occurred in five stent group pa-
tients (7%). Four patients underwent repeat PTCA, and repeat
stenting was performed in three of them. One patient in the
stent group died suddenly 3 months after the procedure, and
this event was attributed to recurrent ischemia. Late recurrent
ischemia occurred in 10 patients (16%) in the PTCA group,
resulting in repeat PTCA in 8 and elective coronary artery
bypass graft surgery (CABG) in 2.
The cumulative early and late recurrent ischemia rate was
lower in the stent group than in the PTCA group (9% vs. 28%,
p 5 0.003). At 6 months, freedom from the composite primary
end point was 87% for the stent group and 68% for the PTCA
group (p 5 0.002) (Fig. 1). Multivariate analysis showed that
the only independent predictor of freedom from recurrent
ischemia was stenting of the IRA (odds ratio 0.304, 95%
confidence interval 0.110 to 0.839, p 5 0.021).
Angiographic outcomes are shown in Table 4. One-month
angiographic follow-up data were available for 143 (97%) of
147 randomized patients eligible for follow-up. The 1-month
restenosis or reocclusion rate was 3% in the stent group and
17% in the PTCA group (p 5 0.004). At the 1-month follow-up
visit, the mean MLD was larger in the stent group than in the
PTCA group (3.06 6 0.71 vs. 2.58 6 1.08 mm, p 5 0.002).
Six-month angiographic follow-up data were available for 124
(95%) of 131 patients eligible for follow-up. The restenosis or
reocclusion rate was lower in the stent group than in the PTCA
group (15% vs. 30%, p 5 0.036). At 6 months, the mean MLD
was larger in the stent group than in the PTCA group (2.36 6
0.88 vs. 2.00 6 1.05 mm, p 5 0.040). At 6-months, the
cumulative incidence of early and late restenosis or reocclusion
was 17% in the stent group and 43% in the PTCA group (p 5
0.001).
Figure 1. Kaplan-Meier curves for freedom from the clinical compos-
ite end point according to treatment group.
Table 2. Procedural Data
Nonrandomized
Group
(n 5 73)
PTCA
Group
(n 5 75)
Stent
Group
(n 5 75)
Primary PTCA failure 3 0 0
IRA stenting 58 (79%) — 75 (100%)
Single stent 34 (59%) — 58 (77%)
Multiple stents 24 (41%) — 17 (23%)
Type of stent
Gianturco-Roubin 55 (63%) — 87 (88%)
Palmaz-Schatz 19 (22%) — 6 (6%)
Microstent 12 (14%) — 3 (3%)
Freedom 1 (1%) — 3 (3%)
Stent deployment
failure
0 — 0
Final balloon inflation
pressure (atm)
14 6 3 9 6 2* 15 6 2
Intraaortic balloon
pump
20 (28%)‡ 8 (11%) 9 (12%)
Procedural duration
(min)
51 6 25† 34 6 28 40 6 19
Final result
Optimal result 62 (85%)‡ 75 (100%) 74 (99%)
Suboptimal result 8 (11%) 0 1 (1%)
Postprocedural QCA
MLD (mm) 3.31 6 0.57 3.03 6 0.46* 3.33 6 0.43
Residual %DS 23 6 12 5 6 8* 24 6 8
*p , 0.01, †p , 0.05 by analysis of variance for comparison among the three
groups. ‡p , 0.05 by chi-square test for comparison among the three groups.
Data presented are mean value 6 SD or number (%) of patients. MLD 5
minimal lumen diameter; QCA 5 quantitative coronary angiography; %DS 5
percent diameter stenosis; — 5 not applicable; other abbreviations as in Table 1.
Table 3. Clinical Outcome of Randomized Patients
PTCA
Group
Stent
Group
p
Value
Early events (0–30 d) n 5 75 n 5 75
Recurrent ischemia 11 (15%) 2 (3%) 0.009
Death 0 0
Reinfarction 2 1 0.560
Repeat target vessel revasc 9 1 0.009
PTCA 9 1
CABG 0 0
Other causes of cardiac death 3 (4%) 0 0.080
Noncardiac death 0 0
Bleeding and vascular compl 3 (4%) 3 (4%)
Late events (31–180 d) n 5 61 n 5 73
Recurrent ischemia 10 (16%) 5 (7%) 0.081
Death 0 1 0.359
Reinfarction 0 0
Repeat target vessel revasc 10 (16%) 4 (5%) 0.040
PTCA 8 4 0.123
CABG 2 0 0.119
Other causes of cardiac death 0 0
Noncardiac death 1 (2%) 0 0.272
All events (0–180 d) n 5 75 n 5 75
Recurrent ischemia 21 (28%) 7 (9%) 0.003
Death 0 1 (1%) 0.316
Reinfarction 2 (3%) 1 (1%) 0.560
Repeat target vessel revasc 19 (25%) 5 (7%) 0.002
PTCA 17 (23%) 5 (7%) 0.006
CABG 2 (3%) 0 0.154
Other causes of cardiac death 3 (4%) 0 0.080
Noncardiac death 1 (1%) 0 0.316
Bleeding and vascular compl 3 (4%) 3 (4%)
Data presented are number (%) of patients. compl 5 complications; d 5
days; revasc 5 revascularization; other abbreviations as in Table 1.
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Clinical and angiographic outcomes of the nonrandomized
patient group. Clinical and angiographic outcomes of the
nonrandomized patient group are summarized in Table 5.
Early recurrent ischemia occurred in three patients (4%). Five
patients with severe multivessel disease were discharged with
the indication to complete myocardial revascularization by
elective CABG. Between 1 and 6 months, recurrent ischemia
occurred in five patients (9%). The cumulative in-hospital and
late recurrent ischemia rate was 11% for the entire group and
12% for patients with a stented IRA. For patients with a
stented IRA, the rate of recurrent ischemia was similar to that
of the randomized stent patient group (12% vs. 9%, p 5 0.610)
and lower than that of the randomized nonstent patient group
(12% vs. 28%, p 5 0.025). Overall, the 6-month cardiac
mortality rate in this group was 10% and was higher than the
3% rate of the combined randomized groups (p 5 0.020). The
excess mortality in this group was mostly due to excess cardiac
deaths for refractory cardiogenic shock.
Angiography was repeated at 6 months in 44 (81%) of 54
patients eligible for the follow-up. The late restenosis and
reocclusion rate was 27%. At 6 months, the mean MLD of the
IRA was 2.18 6 1.11 mm. Cumulative early and late restenosis
and reocclusion rate was 30%.
Discussion
We performed a randomized trial comparing primary IRA
stenting with optimal standard PTCA with respect to major
adverse events related to recurrent ischemia. The study design
included some unique features: 1) Unlike other ongoing trials
that randomize patients to stent or nonstent treatment before
primary PTCA (12–16), FRESCO trial patients were random-
ized only after an optimal angiographic result had been
achieved with standard PTCA, because the potential benefit of
elective coronary stenting as a primary modality treatment in
AMI is unknown. We considered patients with a nonoptimal
angiographic result to be inelegibile for randomization because
several observational studies (6–9) strongly suggest a benefit of
IRA stenting for dissection or a suboptimal angiographic result
after PTCA. 2) To correctly assess the feasibility of stenting
and to avoid the potential bias due to subjective selection of
patients suitable for stenting, the study protocol did not
include any exclusion criterion, except for a reference vessel
diameter ,2.5 mm. 3) Clinical, angiographic and procedural
data were also collected for patients with a nonoptimal angio-
graphic result to assess differences in clinical and angiographic
outcomes compared with those of the randomized patient
groups.
The results of the study confirm the primary study hypoth-
esis. Elective stenting of the IRA resulted in a lower incidence
of aggregate clinical events related to early and late recurrent
ischemia. The cumulative 6-month recurrent ischemia rate was
9% in the stent group and 28% in the PTCA group (p 5
0.003). Consistent with the clinical outcome, angiographic
follow-up showed a significantly lower rate of cumulative
6-month restenosis and reocclusion of the IRA in the stent
group than in the PTCA group (17% vs. 43%, p 5 0.001). The
benefit of coronary stenting in lowering the incidence of
restenosis or reocclusion is evident early, within the first 30
days, and late, from 1 to 6 months after the procedure because
early and late restenosis rates were both significantly lower in
the stent group. In the acute phase, coronary stenting prevents
significant recoil and may correct latent dissection. The latter
mechanism seems to be relevant because in nearly all patients
in the PTCA group with in-hospital recurrent ischemia, emer-
gency coronary angiography revealed occlusive or subocclusive
dissection. In the late phase, the larger postprocedural lumenal
Table 4. Angiographic Outcome of Randomized Patient Groups
PTCA
Group
Stent
Group
p
Value
1-mo follow-up
No. of pts eligible 72 75
Coronary angio done 71 (99%) 72 (96%) 0.331
Early restenosis or reocclusion 12 (17%) 2 (3%) 0.004
MLD (mm) 2.58 6 1.08 3.06 6 0.71 0.002
6-mo follow-up
No. of pts eligible 59 72
Coronary angio done 56 (95%) 68 (94%) 0.905
Late restenosis or reocclusion 17 (30%) 10 (15%) 0.036
MLD (mm) 2.00 6 1.05 2.36 6 0.88 0.040
Cumulative follow-up
No. of pts eligible 71 74
Coronary angio done 68 (96%) 70 (95%) 0.740
All restenoses and
reocclusions
29 (43%) 12 (17%) 0.001
Data presented are mean value 6 SD or number (%) of patients (pts).
angio 5 angiography; other abbreviations as in Tables 1 and 2.
Table 5. Clinical and Angiographic Outcomes of Nonrandomized
Patient Group
Early Events
(0–30 d)
Late Events
(31–180 d)
All Events
(0–180 d)
No of pts with clinical
follow-up
70 57 70
Recurrent ischemia 3 (4%) 5 (9%) 8 (11%)*
Death 1 (1%) 0 1 (1%)
Reinfarction 0 0 0
Target vessel revasc 2 (3%) 5 (9%) 7 (10%)
PTCA 1 2 3
CABG 1 (1%) 3 (5%) 4 (6%)
Other causes of cardiac death 5 (7%) 1 (2%) 6 (9%)
Noncardiac death 0 2 (4%) 2 (3%)
Nontarget CABG 5 (7%) 0 5 (7%)
Bleeding and vascular
complications
5 (7%) 0 5 (7%)
Overall cardiac mortality 6 (9%) 1 (2%) 7 (10%)
No. of pts eligible for angio
follow-up
59 54 56
Coronary angio done 55 (93%) 44 (81%) 46 (82%)
Restenosis or reocclusion 2 (4%) 12 (27%) 14 (30%)
*Seven patients underwent stenting of the infarct-related vessel at the first
procedure; one patient had standard coronary angioplasty only. Data presented
are number (%) of patients. Abbreviations as in Tables 1, 3 and 4.
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diameter provided by stenting (17) and the effect on vascular
remodeling (18) may explain the benefit of stenting in lowering
late restenosis and reocclusion rates.
A substantial minority (33%) of patients eligible for pri-
mary PTCA were not eligible for randomization to elective
stent treatment. Nearly all these patients underwent nonelective
coronary stenting. Although stenting was frequently accom-
plished as a rescue procedure, and multiple stent implantation
was needed in many patients, the rate of recurrent ischemia was
only slightly higher than that of the stent group and lower than
that of the PTCA group. Thus, nonelective stenting, as well as
primary elective stenting, may lower the incidence of early and
late major adverse events related to recurrent ischemia.
IRA stenting may be considered highly feasible because
there were no stent deployment failures. This high procedural
success rate was achieved with the use of the Gianturco-
Roubin stent as the first-choice device, whose trackability
allows successful placement even in unfavorable anatomic
settings. Preliminary results of other trials (12,13,15,16) sug-
gest that the feasibility of primary stenting of the IRA may be
high, even when other types of stents are used. However, in
those studies, stenting was not attempted in a substantial
minority of patients who were considered unsuitable for stent-
ing because of unfavorable anatomic characteristics.
Conclusions. The results of the present trial suggest that
primary stenting of the IRA results in improved 6-month
outcome as a consequence of a lower incidence of major
cardiac events related to recurrent ischemia. Thus, stenting
might be considered a primary treatment modality for patients
with an AMI.
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